Ulrike Eggert, PhD
Office phone: 617-582-8581
Preferred contact method: email
Area of ResearchCytokinesis
Dana-Farber Cancer Institute
450 Brookline Avenue
Seeley G. Mudd 620
Boston, MA 02215
Ulrike Eggert received her PhD in chemistry from Princeton University in 2001. Following her postdoctoral research with Tim Mitchison at Harvard Medical School in the Department of Systems Biology, Dr. Eggert has recently joined the faculty of Harvard Medical School and DFCI to continue her study of cytokinesis using a combination of chemical genetics and RNAi.
How do cells divide? Chromosomes divide during mitosis and cells physically divide during cytokinesis. Cytokinesis, the final step in cell division, involves the coordinated action of the cytoskeleton, the cell cycle engine and membrane transport machineries. Traditionally, cytokinesis has been difficult to study because it is a very rapid and dynamic process that occupies only a small portion of the cell cycle. Many key cytokinesis proteins also perform essential functions earlier in the cell cycle and their removal leads to an arrest prior to cytokinesis. Since small molecules act rapidly and reversibly and can be added at specific points in the cell cycle for live analysis, they are ideal to study cytokinesis. We use a combination of chemical genetics and RNAi to generate new small molecule tools that affect cytokinesis.
We discovered several promising small molecule inhibitors of cytokinesis by high-throughput screening and we are currently identifying and characterizing their cellular targets. A major focus is to use these novel drugs to probe cytokinesis mechanism by a variety of techniques including live imaging and biochemistry.
In addition to small molecules that affect a process (cytokinesis) and specific proteins (small molecule targets), we are excited about developing chemical tools to study biological pathways. The Rho pathway is responsible for regulating many important cellular events, including cytokinesis, but little is known about the mechanisms involved. We combine chemical approaches and RNAi to develop small molecules and to identify proteins that affect the Rho pathway.
A first step towards understanding a process is to know which proteins are involved. We made the first comprehensive list of cytokinesis proteins by genome-wide RNAi screening and found many new proteins with interesting cytokinesis phenotypes. We are interested in elucidating the functions of some of these proteins, possibly by using specific small molecule inhibitors.
For more information, please visit our Web site at http://research.dfci.harvard.edu/eggert_lab/.
- Perrimon N, Friedman A, Mathey-Prevot B, Eggert US. Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens. Drug Discov Today 2007;12:28-33.
- Eggert US, Field CM, Mitchison TJ. Small molecules in an RNAi world. Mol Biosyst 2006;2:93-6.
- Eggert US, Mitchison TJ, Field CM. Animal cytokinesis: from parts list to mechanisms. Annu Rev Biochem 2006;75:543-66.
- Eggert US, Mitchison TJ. Small molecule screening by imaging. Curr Opin Chem Biol 2006;10:232-7.
- Eggert US, Kiger AA, Richter C, Perlman ZE, Perrimon N, Mitchison TJ, Field CM. Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol 2004;2:e379.
- Castoreno, Adam, PhD